Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 168625
Corporate User License Price USD 7500
Corporate User License Price INR 505875
Site License Price USD 5000
Site License Price INR 337250
Request a Quote

Report Title

Gastric Cancer-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Gastric Cancer-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Gastric Cancer-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Gastric Cancer-Pipeline Review, H1 2017



Executive Summary

Gastric Cancer-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer-Pipeline Review, H1 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 14, 70, 77, 7, 74, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 8 and 1 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 8

Gastric Cancer-Overview 9

Gastric Cancer-Therapeutics Development 10

Gastric Cancer-Therapeutics Assessment 40

Gastric Cancer-Companies Involved in Therapeutics Development 58

Gastric Cancer-Drug Profiles 131

Gastric Cancer-Dormant Projects 935

Gastric Cancer-Discontinued Products 943

Gastric Cancer-Product Development Milestones 946

Appendix 954

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Gastric Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Gastric Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gastric Cancer-Pipeline by 3SBio Inc, H1 2017

Gastric Cancer-Pipeline by AB Science SA, H1 2017

Gastric Cancer-Pipeline by AbbVie Inc, H1 2017

Gastric Cancer-Pipeline by AbGenomics International Inc, H1 2017

Gastric Cancer-Pipeline by Abion Inc, H1 2017

Gastric Cancer-Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Gastric Cancer-Pipeline by ADC Therapeutics Sarl, H1 2017

Gastric Cancer-Pipeline by Aduro BioTech Inc, H1 2017

Gastric Cancer-Pipeline by Advaxis Inc, H1 2017

Gastric Cancer-Pipeline by Advenchen Laboratories LLC, H1 2017

Gastric Cancer-Pipeline by Agenus Inc, H1 2017

Gastric Cancer-Pipeline by Almac Discovery Ltd, H1 2017

Gastric Cancer-Pipeline by Alteogen Inc, H1 2017

Gastric Cancer-Pipeline by Ambrx Inc, H1 2017

Gastric Cancer-Pipeline by amcure GmbH, H1 2017

Gastric Cancer-Pipeline by Amgen Inc, H1 2017

Gastric Cancer-Pipeline by ANP Technologies Inc, H1 2017

Gastric Cancer-Pipeline by Antikor Biopharma Ltd, H1 2017

Gastric Cancer-Pipeline by arGEN-X BV, H1 2017

Gastric Cancer-Pipeline by Array BioPharma Inc, H1 2017

Gastric Cancer-Pipeline by Asana BioSciences LLC, H1 2017

Gastric Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Gastric Cancer-Pipeline by Astellas Pharma Inc, H1 2017

Gastric Cancer-Pipeline by AstraZeneca Plc, H1 2017

Gastric Cancer-Pipeline by Athenex Inc, H1 2017

Gastric Cancer-Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Gastric Cancer-Pipeline by Bayer AG, H1 2017

Gastric Cancer-Pipeline by BeiGene Ltd, H1 2017

Gastric Cancer-Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Gastric Cancer-Pipeline by Bionovis SA, H1 2017

Gastric Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Gastric Cancer-Pipeline by Boston Biomedical Inc, H1 2017

Gastric Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2017

Gastric Cancer-Pipeline by Camel-IDS NV, H1 2017

Gastric Cancer-Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by CBT Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Celgene Corp, H1 2017

Gastric Cancer-Pipeline by Celldex Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Cellectar Biosciences Inc, H1 2017

Gastric Cancer-Pipeline by Celltrion Inc, H1 2017

Gastric Cancer-Pipeline by Celon Pharma SA, H1 2017

Gastric Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2017

Gastric Cancer-Pipeline by Curaxys SL, H1 2017

Gastric Cancer-Pipeline by Cytori Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Gastric Cancer-Pipeline by Debiopharm International SA, H1 2017

Gastric Cancer-Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Gastric Cancer-Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Gastric Cancer-Pipeline by Eli Lilly and Company, H1 2017

Gastric Cancer-Pipeline by EOS Biosciences Inc, H1 2017

Gastric Cancer-Pipeline by Erytech Pharma SA, H1 2017

Gastric Cancer-Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Exelixis Inc, H1 2017

Gastric Cancer-Pipeline by F-star Biotechnology Ltd, H1 2017

Gastric Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Gastric Cancer-Pipeline by Five Prime Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Frost Biologic Inc, H1 2017

Gastric Cancer-Pipeline by Galena Biopharma Inc, H1 2017

Gastric Cancer-Pipeline by Genelux Corp, H1 2017

Gastric Cancer-Pipeline by Genentech Inc, H1 2017

Gastric Cancer-Pipeline by Gilead Sciences Inc, H1 2017

Gastric Cancer-Pipeline by GlaxoSmithKline Plc, H1 2017

Gastric Cancer-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Gastric Cancer-Pipeline by GlycoNex Inc, H1 2017

Gastric Cancer-Pipeline by Glycotope GmbH, H1 2017

Gastric Cancer-Pipeline by Green Cross Corp, H1 2017

Gastric Cancer-Pipeline by Halozyme Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Gastric Cancer-Pipeline by Horizon Pharma Plc, H1 2017

Gastric Cancer-Pipeline by Hutchison China MediTech Ltd, H1 2017

Gastric Cancer-Pipeline by Ignyta Inc, H1 2017

Gastric Cancer-Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Immunomedics Inc, H1 2017

Gastric Cancer-Pipeline by Incyte Corp, H1 2017

Gastric Cancer-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Inspyr Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Insys Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Intezyne Technologies Inc, H1 2017

Gastric Cancer-Pipeline by Ipsen SA, H1 2017

Gastric Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Gastric Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Johnson & Johnson, H1 2017

Gastric Cancer-Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Gastric Cancer-Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by LegoChem Biosciences Inc, H1 2017

Gastric Cancer-Pipeline by Les Laboratoires ServierSAS, H1 2017

Gastric Cancer-Pipeline by MacroGenics Inc, H1 2017

Gastric Cancer-Pipeline by MaxiVAX SA, H1 2017

Gastric Cancer-Pipeline by Mebiopharm Co Ltd, H1 2017

Gastric Cancer-Pipeline by MedImmune LLC, H1 2017

Gastric Cancer-Pipeline by Merck & Co Inc, H1 2017

Gastric Cancer-Pipeline by Merck KGaA, H1 2017

Gastric Cancer-Pipeline by Mersana Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Merus NV, H1 2017

Gastric Cancer-Pipeline by Mirati Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Molecular Partners AG, H1 2017

Gastric Cancer-Pipeline by Molecular Targeting Technologies Inc, H1 2017

Gastric Cancer-Pipeline by MolMed SpA, H1 2017

Gastric Cancer-Pipeline by NanoCarrier Co Ltd, H1 2017

Gastric Cancer-Pipeline by Novartis AG, H1 2017

Gastric Cancer-Pipeline by Novogen Ltd, H1 2017

Gastric Cancer-Pipeline by OBI Pharma Inc, H1 2017

Gastric Cancer-Pipeline by Oncobiologics Inc, H1 2017

Gastric Cancer-Pipeline by Oncolys BioPharma Inc, H1 2017

Gastric Cancer-Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Opsona Therapeutics Ltd, H1 2017

Gastric Cancer-Pipeline by Panacea Biotec Ltd, H1 2017

Gastric Cancer-Pipeline by Patrys Ltd, H1 2017

Gastric Cancer-Pipeline by Pfizer Inc, H1 2017

Gastric Cancer-Pipeline by Pharma Mar SA, H1 2017

Gastric Cancer-Pipeline by Plexxikon Inc, H1 2017

Gastric Cancer-Pipeline by Puma Biotechnology Inc, H1 2017

Gastric Cancer-Pipeline by Redx Pharma Plc, H1 2017

Gastric Cancer-Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Rgenix Inc, H1 2017

Gastric Cancer-Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Gastric Cancer-Pipeline by Richter Gedeon Nyrt, H1 2017

Gastric Cancer-Pipeline by Samumed LLC, H1 2017

Gastric Cancer-Pipeline by Sanofi, H1 2017

Gastric Cancer-Pipeline by Selecta Biosciences Inc, H1 2017

Gastric Cancer-Pipeline by Sequella Inc, H1 2017

Gastric Cancer-Pipeline by Shionogi & Co Ltd, H1 2017

Gastric Cancer-Pipeline by Simcere Pharmaceutical Group, H1 2017

Gastric Cancer-Pipeline by Sorrento Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Gastric Cancer-Pipeline by Stelic Institute & Co Inc, H1 2017

Gastric Cancer-Pipeline by Supratek Pharma Inc, H1 2017

Gastric Cancer-Pipeline by SynCore Biotechnology Co Ltd, H1 2017

Gastric Cancer-Pipeline by Synovo GmbH, H1 2017

Gastric Cancer-Pipeline by Synthon Holdings BV, H1 2017

Gastric Cancer-Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Gastric Cancer-Pipeline by Taiwan Liposome Company Ltd, H1 2017

Gastric Cancer-Pipeline by Takis Srl, H1 2017

Gastric Cancer-Pipeline by Tessa Therapeutics Pte Ltd, H1 2017

Gastric Cancer-Pipeline by Transgene SA, H1 2017

Gastric Cancer-Pipeline by United BioPharma Inc, H1 2017

Gastric Cancer-Pipeline by Vaxon Biotech, H1 2017

Gastric Cancer-Pipeline by Viracta Therapeutics Inc, H1 2017

Gastric Cancer-Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Gastric Cancer-Pipeline by Zymeworks Inc, H1 2017

Gastric Cancer-Dormant Projects, H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..1), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..2), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..3), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..4), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..5), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..6), H1 2017

Gastric Cancer-Dormant Projects, H1 2017 (Contd..7), H1 2017

Gastric Cancer-Discontinued Products, H1 2017

Gastric Cancer-Discontinued Products, H1 2017 (Contd..1), H1 2017

Gastric Cancer-Discontinued Products, H1 2017 (Contd..2), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

3SBio Inc, AB Science SA, AbbVie Inc, AbGenomics International Inc, Abion Inc, Adaptimmune Therapeutics Plc, ADC Therapeutics Sarl, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC, Agenus Inc, Almac Discovery Ltd, Alteogen Inc, Ambrx Inc, amcure GmbH, Amgen Inc, ANP Technologies Inc, Antikor Biopharma Ltd, arGEN-X BV, Array BioPharma Inc, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Basilea Pharmaceutica Ltd, Bayer AG, BeiGene Ltd, Beijing Hanmi Pharmaceutical Co Ltd, Betta Pharmaceuticals Co Ltd, Bionovis SA, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Camel-IDS NV, Cancer Prevention Pharmaceuticals Inc, CBT Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celltrion Inc, Celon Pharma SA, Chipscreen Biosciences Ltd, Curaxys SL, Cytori Therapeutics Inc, Daiichi Sankyo Company Ltd, Debiopharm International SA, Deciphera Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, EOS Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Exelixis Inc, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Frost Biologic Inc, Galena Biopharma Inc, Genelux Corp, Genentech Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GlycoNex Inc, Glycotope GmbH, Green Cross Corp, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Horizon Pharma Plc, Hutchison China MediTech Ltd, Ignyta Inc, Ildong Pharmaceutical Co Ltd, Immunomedics Inc, Incyte Corp, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, Insys Therapeutics Inc, Intezyne Technologies Inc, Ipsen SA, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kuhnil Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, LATITUDE Pharmaceuticals Inc, LegoChem Biosciences Inc, Les Laboratoires ServierSAS, MacroGenics Inc, MaxiVAX SA, Mebiopharm Co Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Mersana Therapeutics Inc, Merus NV, Mirati Therapeutics Inc, Molecular Partners AG, Molecular Targeting Technologies Inc, MolMed SpA, NanoCarrier Co Ltd, Novartis AG, Novogen Ltd, OBI Pharma Inc, Oncobiologics Inc, Oncolys BioPharma Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Opsona Therapeutics Ltd, Panacea Biotec Ltd, Patrys Ltd, Pfizer Inc, Pharma Mar SA, Plexxikon Inc, Puma Biotechnology Inc, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rgenix Inc, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Samumed LLC, Sanofi, Selecta Biosciences Inc, Sequella Inc, Shionogi & Co Ltd, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc, Spectrum Pharmaceuticals Inc, Stelic Institute & Co Inc, Supratek Pharma Inc, SynCore Biotechnology Co Ltd, Synovo GmbH, Synthon Holdings BV, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takis Srl, Tessa Therapeutics Pte Ltd, Transgene SA, United BioPharma Inc, Vaxon Biotech, Viracta Therapeutics Inc, XuanZhu Pharma Co Ltd, Zymeworks Inc

Gastric Cancer Therapeutic Products under Development, Key Players in Gastric Cancer Therapeutics, Gastric Cancer Pipeline Overview, Gastric Cancer Pipeline, Gastric Cancer Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand